ZA201000085B - 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors - Google Patents

2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors

Info

Publication number
ZA201000085B
ZA201000085B ZA201000085A ZA201000085A ZA201000085B ZA 201000085 B ZA201000085 B ZA 201000085B ZA 201000085 A ZA201000085 A ZA 201000085A ZA 201000085 A ZA201000085 A ZA 201000085A ZA 201000085 B ZA201000085 B ZA 201000085B
Authority
ZA
South Africa
Prior art keywords
benzoxazol
tumors
oxo
benzyl
derivatives
Prior art date
Application number
ZA201000085A
Other languages
English (en)
Inventor
Oliver Schadt
Dieter Dorsch
Frank Stieber
Andree Blaukat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA201000085B publication Critical patent/ZA201000085B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA201000085A 2007-06-06 2010-01-05 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors ZA201000085B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007026341A DE102007026341A1 (de) 2007-06-06 2007-06-06 Benzoxazolonderivate

Publications (1)

Publication Number Publication Date
ZA201000085B true ZA201000085B (en) 2010-09-29

Family

ID=39739806

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201000085A ZA201000085B (en) 2007-06-06 2010-01-05 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors

Country Status (18)

Country Link
US (2) US8071593B2 (xx)
EP (1) EP2150551B1 (xx)
JP (1) JP5662143B2 (xx)
KR (1) KR20100031531A (xx)
CN (1) CN101679401B (xx)
AR (1) AR066892A1 (xx)
AU (1) AU2008258366B2 (xx)
BR (1) BRPI0812293A2 (xx)
CA (1) CA2689554C (xx)
DE (1) DE102007026341A1 (xx)
EA (1) EA200901611A1 (xx)
ES (1) ES2402540T3 (xx)
IL (1) IL202505A (xx)
MX (1) MX2009013077A (xx)
PE (1) PE20090770A1 (xx)
TW (1) TW200848030A (xx)
WO (1) WO2008148449A1 (xx)
ZA (1) ZA201000085B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009143477A1 (en) * 2008-05-22 2009-11-26 Amgen Inc. Heterocycles as protein kinase inhibitors
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
JP2012500260A (ja) * 2008-08-18 2012-01-05 イェール・ユニヴァーシティー Ｍｉｆモジュレーター
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
UA103646C2 (ru) 2008-12-22 2013-11-11 Мерк Патент Гмбх Полиморфные формы 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илетокси)-пиримидин-2-ил]-бензил}-2h-пиридазин-3-она и способ их получения (варианты)
DE102009003975A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2013003383A1 (en) 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
CN103242345B (zh) * 2012-09-14 2015-03-11 日出实业集团有限公司 甲基吡啶磷中间体6-氯噁唑[4,5-b]吡啶-2(3H)酮的合成方法
AR095883A1 (es) * 2013-04-18 2015-11-18 Astellas Pharma Inc Compuestos de acetamida heterocíclica
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
CN111465602B (zh) 2017-10-17 2023-05-23 帕劳制药有限公司 4-氨基嘧啶化合物的合成
US20220151991A1 (en) 2019-03-14 2022-05-19 Board Of Regents, The University Of Texas System Small molecule grb2 stabilizers for ras map kinase inhibition
CN115490578B (zh) * 2022-09-23 2023-12-22 江苏理工学院 一种碳同位素标记的三氯生的制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS421467B1 (xx) * 1963-11-28 1967-01-24
DE3904797A1 (de) 1989-02-17 1990-08-30 Merck Patent Gmbh Nichtlinear optische materialien mit vicinalen donor- und akzeptorgruppen
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
JP4342935B2 (ja) 2001-06-22 2009-10-14 協和発酵キリン株式会社 肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
EP1463509A1 (en) 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
EP1463505A2 (en) * 2001-12-13 2004-10-06 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
JP4399269B2 (ja) 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
CA2510298A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
CA2530589A1 (en) 2003-07-02 2005-01-20 Sugen Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
DE102004036581A1 (de) 2004-07-28 2006-03-23 Robert Bosch Gmbh Verfahren zum Betreiben eines Hybridantriebs und Vorrichtung zur Durchführung des Verfahrens
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
CH697191A5 (de) 2004-07-29 2008-06-25 Biospectra Ag Mehrfach-Bioreaktorvorrichtung.
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
EP1621785A1 (en) 2004-07-30 2006-02-01 Mecos Traxler AG Method and apparatus for controlling a magnetic bearing device
EP1784396B8 (en) 2004-08-26 2011-04-20 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
KR101412675B1 (ko) 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. 티로신 키나제 모듈레이터로서의 트리아졸로피리다진
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
AR068876A1 (es) 2007-10-16 2009-12-09 Novartis Ag Heterociclos utiles como modulador de los receptores npy y y2 y composiciones farmaceuticas que los contienen
CN101910158A (zh) 2007-10-25 2010-12-08 阿斯利康(瑞典)有限公司 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物
MX2010004705A (es) 2007-10-31 2010-05-27 Nissan Chemical Ind Ltd Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
CL2008003407A1 (es) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CL2008003799A1 (es) 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
KR101610607B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
TW200930375A (en) 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones
PL2235012T3 (pl) 2007-12-21 2013-12-31 Palau Pharma Sa Pochodne 4-amino-pirymidyny jako antagoniści receptora H<sub>4</sub> histaminowego
NZ586913A (en) 2007-12-21 2012-06-29 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
JP5253143B2 (ja) 2008-12-26 2013-07-31 キヤノン株式会社 情報処理装置、情報処理装置の制御方法、及びプログラム
US20120028988A1 (en) 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
CN101679401B (zh) 2012-12-12
WO2008148449A1 (de) 2008-12-11
EA200901611A1 (ru) 2010-06-30
DE102007026341A1 (de) 2008-12-11
CA2689554C (en) 2015-12-01
AR066892A1 (es) 2009-09-16
KR20100031531A (ko) 2010-03-22
BRPI0812293A2 (pt) 2014-11-25
CA2689554A1 (en) 2008-12-11
US8071593B2 (en) 2011-12-06
AU2008258366A1 (en) 2008-12-11
CN101679401A (zh) 2010-03-24
PE20090770A1 (es) 2009-06-24
US20100280030A1 (en) 2010-11-04
IL202505A0 (en) 2010-06-30
EP2150551B1 (de) 2013-01-16
JP2010529051A (ja) 2010-08-26
AU2008258366B2 (en) 2013-02-21
TW200848030A (en) 2008-12-16
ES2402540T3 (es) 2013-05-06
US8431572B2 (en) 2013-04-30
MX2009013077A (es) 2010-01-15
EP2150551A1 (de) 2010-02-10
US20110263596A1 (en) 2011-10-27
JP5662143B2 (ja) 2015-01-28
IL202505A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
PL2120932T3 (pl) Indazolowe pochodne jako inhibitory kinazy do leczenia raka
HK1254663A1 (zh) 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2148677A4 (en) KINASEHEMMER FOR THE TREATMENT OF MYLEOPROLIFERATIVE AND OTHER PROLIFERATIVE DISEASES
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL202317A0 (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EP2429292A4 (en) COMPOUNDS AND COMPOSITIONS WITH CDK INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL211825A0 (en) Pyridine and pyrimidine based compounds as wnt sigaling pathway inhibitors for the treatment of cancer
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
HK1144392A1 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
EP2164517A4 (en) IL-18 AND PROTEIN KINASE-R INHIBITION FOR THE TREATMENT OF COPD
HK1151971A1 (en) Compounds for use in the treatment of cancer
EP2331092A4 (en) METHOD AND COMPOSITIONS FOR THE ADMINISTRATION OF 3-HALOPYRUVATE AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER
IL226363A0 (en) Compounds and methods for treating cancer
HK1157345A1 (en) Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors
HK1209754A1 (en) Compounds and methods for the treatment of cancer